Legend Biotech Corporation (NASDAQ: LEGN) has become one of biotech’s most debated recovery stories. The company is a commercial-stage cell therapy developer best known for Carvykti, a CAR-T treatment for multiple myeloma. With shares changing hands near $20.60 after the latest analyst-driven pullback, investors are asking whether LEGN can realistically climb to $40, a move that would require roughly 90% upside.
The $40 stock price target is not arbitrary. Oppenheimer recently cut its LEGN target to $40 from $75 while downgrading the stock to Market Perform, keeping the round-number level in public market discussion. Because LEGN’s 52-week high is $38.35, reaching $40 would require clearing the stock’s prior peak and establishing a new uptrend. For a stock trading near $20.60, that is a major technical and psychological hurdle rather than a routine extension.
LEGN closed the prior session at $21.83 after a strong earnings-driven gain, but the latest session brought renewed pressure. TD Cowen lowered its target to $24 from $29, and Oppenheimer’s downgrade underscored concerns about strategy and competition. The stock has had a volatile year: it rallied toward the upper $30s in June before a discounted share offering, a CEO departure, and competitive fears erased those gains. LEGN now carries a market capitalization near $3.9 billion and remains far below its 52-week high.
The fundamental case for a recovery toward $40 is grounded in improving commercial execution. In the second quarter, LEGN reported adjusted earnings of $0.09 per share, above the $0.07 consensus, while revenue rose 51.9% year over year to $387.5 million. Management highlighted roughly $657 million in worldwide net trade sales for Carvykti, up about 50%, and said the company achieved its first quarter of company-wide profitability on both IFRS and adjusted bases.
Beyond Carvykti, Legend Biotech’s in vivo CAR-T program offers a potential second growth engine. Early Phase 1 data in B-cell non-Hodgkin lymphoma showed all six treated patients responded, with five complete responses. That level of early efficacy has kept long-term pipeline enthusiasm alive even as sentiment has deteriorated. A strengthened balance sheet from the recent capital raise also gives the company room to fund additional development.
The obstacles are equally significant. The departure of CEO Ying Huang has increased strategic uncertainty at a delicate commercial moment. Oppenheimer also pointed to Johnson & Johnson (NYSE: JNJ) partnering with Sail Biomedicines, which removes what many investors viewed as the most likely near-term acquisition scenario for LEGN.
Competition is intensifying. Gilead Sciences’ anitocel is moving toward commercialization, while IQVIA data cited by analysts suggested softer Carvykti sales trends and stronger uptake for competing therapies. The June equity offering, priced at a double-digit discount, also weighed on investor confidence. Technically, LEGN must first reclaim supply zones near $23 and the $28–$29 area before a credible push toward the prior high near $38.35.
Wall Street remains divided. Published 12-month targets span from $24 to $78, with the consensus average around $52 but the rating mix now closer to Hold than a clear Buy. That wide range reflects genuine uncertainty about leadership, commercial durability, and pipeline timelines. The $40 objective sits below the average target, but it would still require LEGN to outperform several recently reduced expectations.
On the chart, nearby support appears near $20.50 and then the $19 area, with the 52-week low at $16.24. Resistance is layered: the $23 zone is the first test, followed by $28–$29 and then the prior high near $38.35. A sustained move through those levels would be needed to make $40 realistic.
Tickeron’s AI Daily Buy/Sell Signals help traders monitor stocks and ETFs by using artificial intelligence to scan thousands of securities and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like LEGN, such tools can help investors identify shifting trends, track potential entry or exit conditions, and monitor existing positions more efficiently. Traders can use the platform to discover new opportunities and stay more responsive to evolving market signals.
Reaching $40 appears ambitious from a base near $20.60, because it would require a near-doubling and a new 52-week high. The strongest arguments for the move are accelerating Carvykti revenue, the company’s first quarterly profitability, and an in vivo CAR-T pipeline with meaningful long-term optionality. The main risks are leadership uncertainty, competitive pressure, diminished M&A prospects, and the stock’s current position below multiple technical resistance zones. For $40 to become realistic, investors would likely need to see a credible new CEO, renewed Carvykti sales momentum, and additional validating data from the broader pipeline. Until then, the target remains a possible but demanding objective rather than a near-term expectation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, LEGN has been loosely correlated with AXON. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if LEGN jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To LEGN | 1D Price Change % | ||
|---|---|---|---|---|
| LEGN | 100% | +2.63% | ||
| AXON - LEGN | 37% Loosely correlated | +2.20% | ||
| AMLX - LEGN | 35% Loosely correlated | -2.52% | ||
| WVE - LEGN | 31% Poorly correlated | +0.76% | ||
| AMRN - LEGN | 31% Poorly correlated | +0.21% | ||
| ARRY - LEGN | 30% Poorly correlated | -0.42% | ||
More | ||||